Clinical trials: Ulcerative Colitis (UC)
Ulcerative Colitis (UC)
Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis
What is the research question being addressed? Does combining Turbinaria ornata-derived fucoidan with standard therapy lead to a significantly higher rate of gut health restoration-defined by increased fecal short-chain fatty…
- Trial name
- SEA-GUT (NCT07786389)
- Testing
- Low molecular weight fucoidan and standard care
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Allama Iqbal Medical College
Inflammatory Bowel Diseases, Crohn Disease
Inflammatory Biomarkers and Disease Activity in Inflammatory Bowel Disease
This study aims to evaluate the diagnostic accuracy and clinical utility of routine blood-derived inflammatory biomarker ratios in assessing disease activity among adult patients with inflammatory bowel disease (IBD), including…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis (UC)
- Trial name
- NCT07788131
- Volunteers
- 120 people
- Sponsor
- Assiut University
Etrasimod, Mesalazine
Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC
Ulcerative colitis (UC) is a chronic, relapsing inflammatory disease of the colon that causes diarrhea, bleeding, and abdominal pain.
- Conditions
- Etrasimod, Mesalazine, Ulcerative Colitis (UC), Head-to-head
- Trial name
- E-Compare (NCT07782242)
- Testing
- Etrasimod, mesalazine
- Volunteers
- 320 people
- Sponsor
- Sir Run Run Shaw Hospital
Ulcerative Colitis (UC), Pouchitis
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch Surgery
Ulcerative colitis (UC) is a chronic intestinal disease, often debuting early in life, and affecting the colon and rectum. The therapy is mainly medical and based on 5-aminosalicylic acid (5-ASA) and steroids.
- Trial name
- ASAPP (NCT07773948)
- Testing
- 5-ASA
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- University Hospital, Linkoeping
Ulcerative Colitis (UC)
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Ponesimod (VSP-128) in patients with moderately to severely active ulcerative colitis
- Trial name
- NCT07686081
- Testing
- Ponesimod
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Vanda Pharmaceuticals
Ulcerative Colitis (UC)
A Study of AC-101 Tablets in Patients With Ulcerative Colitis
This is a Phase Ⅱb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding study of AC-101 tablets in patients with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT07755241
- Testing
- AC-101
- Volunteers
- 153 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Diarrhea Chronic, UC - Ulcerative Colitis
ND-12 Combined With H-6 for Adult Chronic Inflammatory Diarrhea
This is a randomized controlled trial to explore the efficacy and safety of ND-12 combined with H-6 for patients with chronic inflammatory diarrhea
- Trial name
- NCT07767370
- Testing
- mesalazine, ND-12, ND-12/H-6
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Ulcerative Colitis (UC), Crohn Disease (CD)
The Safety and Efficacy of Good Feeling Power® for IBD Patients
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
- Trial name
- NCT07766733
- Testing
- Good Feeling Power®
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Good Feeling Products GmbH
Inflammatory Bowel Diseases (IBD), Crohns Disease
Development and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS)
Children with inflammatory bowel disease (IBD) including both Crohn's disease (CD) and ulcerative colitis (UC) can be at high risk of developing malnutrition due to the nature of their condition.
- Conditions
- Inflammatory Bowel Diseases (IBD), Crohns Disease, Ulcerative Colitis (UC)
- Trial name
- PIBD-NUTS (NCT06723418)
- Testing
- Malnutriton Screening Tool (PYMS)
- Where
- 8 sites in Austria, Croatia and 4 more
- Volunteers
- 2,000 people
- Sponsor
- University of Glasgow
Inflammatory Bowel Diseases (IBD), Remission of IBD
VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
The VIBRANT-IBD study is a pilot, prospective, single-arm feasibility study investigating the effects of non-invasive vagus nerve stimulation (nVNS) in adults with inflammatory bowel disease (IBD) in clinical remission.
- Conditions
- Inflammatory Bowel Diseases (IBD), Remission of IBD, In Adults, Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- Trial name
- VIBRANT-IBD (NCT07636304)
- Testing
- Non-invasive vagus nerve stimulation (nVNS)
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- University of Gdansk
Ulcerative Colitis (UC)
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of PTT-621 in Patients With Moderately to Severely Active Ulcerative Colitis
This Phase IIa, multicenter, single-arm trial evaluates the efficacy, safety, tolerability, and pharmacokinetics of PTT-621 tablets in adults (18-70 years) with moderate-to-severe active ulcerative colitis (UC) who have…
- Trial name
- NCT07747155
- Testing
- PTT-621 Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Pyrotech Therapeutics, Inc.
Ulcerative Colitis (UC), Crohn's Disease (CD)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals…
- Conditions
- Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
- Trial name
- ZEST (NCT07237516)
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis (UC)
Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis
The purpose of this protocol is to evaluate the safety and efficacy of Alpha-0261 in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT07744646
- Testing
- Alpha-0261
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Ulcerative Colitis (UC)
The Fecal Immunoassay Occult Blood Test Combined With Calprotectin Sequential Linkage Imaging Endoscopy Screening Strategy for Monitoring Tumor Changes Associated With Long-duration Ulcerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with an increased risk of colorectal cancer, known as UC-associated neoplasia (UCAN).
- Trial name
- DETECT-UCAN (NCT07742410)
- Volunteers
- 250 people
- Sponsor
- Qilu Hospital of Shandong University
Ulcerative Colitis (UC)
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
This multicenter retrospective comparative cohort study evaluated the real-world effectiveness and safety of upadacitinib plus vedolizumab compared with upadacitinib monotherapy during 8-week induction in adults with…
- Trial name
- NCT07442045
- Testing
- Upadacitinib, Vedolizumab
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis (UC)
Efficacy of Upadacitinib Re-induction Therapy in Patients With Ulcerative Colitis Who Lost Response to 30 mg Maintenance Dose
ReCOUP is a multicenter clinical study designed to evaluate the efficacy of upadacitinib (Rinvoq®) in patients with ulcerative colitis whose disease has become active again despite maintenance treatment with upadacitinib 30 mg.
- Trial name
- ReCOUP (NCT07700446)
- Testing
- Upadacitinib
- Volunteers
- 100 people
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
IBD (Inflammatory Bowel Disease), Ulcerative Colitis (UC)
Assessing Interventions of Diet in IBD
In this study, we are trying to learn how certain diets affect people with inflammatory bowel disease (IBD). We want to understand what makes it hard or easy for them to stick to different eating plans, like intermittent fasting…
- Conditions
- IBD (Inflammatory Bowel Disease), Ulcerative Colitis (UC), Crohn Disease (CD)
- Trial name
- AID-IBD (NCT06773182)
- Testing
- Intermittent Fasting Intervention, Mediterranean Diet Intervention, Low FODMAP Diet Intervention
- Where
- 2 sites in Canada
- Volunteers
- 45 people
- Sponsor
- McMaster University
Ulcerative Colitis (UC), Fecal Calprotetin
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
This multicenter prospective cohort study aims to evaluate whether a >50% decrease or normalization of both quantitative fecal immunochemical test (qFIT) and fecal calprotectin (FC) levels at 2 weeks after starting conventional…
- Conditions
- Ulcerative Colitis (UC), Fecal Calprotetin, FIT, Biomarker
- Trial name
- DYNAMIC-UC (NCT07111273)
- Testing
- FC and FIT TEST at WEEK0 2 4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Ulcerative Colitis (UC), Fecal Calprotetin
Fecal biOmarker Response Evaluation for Super-Early Efficacy in Ulcerative Colitis
This multicenter prospective cohort aims to evaluate whether combined changes in fecal calprotectin (FC) and fecal immunochemical test (FIT) at Week 2 and Week 4 after initiating biologic therapy (vedolizumab or infliximab) can…
- Conditions
- Ulcerative Colitis (UC), Fecal Calprotetin, FIT
- Trial name
- FORESEE-UC (NCT07111572)
- Testing
- fecal calprotectin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Ulcerative Colitis (UC)
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
This study will evaluate the efficacy and safety of 627 in patients with UC.
- Trial name
- NCT07507513
- Testing
- 627
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.